Krystal Biotech (NASDAQ:KRYS) Given "Buy" Rating at HC Wainwright

Krystal Biotech (NASDAQ:KRYS - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $240.00 target price on the stock. HC Wainwright's price objective would indicate a potential upside of 70.36% from the stock's previous close.

Other equities analysts also recently issued reports about the company. Citigroup raised their price objective on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research report on Thursday, February 20th. Jefferies Financial Group initiated coverage on Krystal Biotech in a report on Wednesday, March 5th. They set a "buy" rating and a $245.00 price objective on the stock. Chardan Capital upped their price objective on Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a report on Thursday, February 20th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 price objective on shares of Krystal Biotech in a report on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $222.71.

Krystal Biotech Stock Performance

Shares of KRYS traded down $21.41 during mid-day trading on Tuesday, hitting $140.88. The company's stock had a trading volume of 685,473 shares, compared to its average volume of 296,502. Krystal Biotech has a one year low of $137.57 and a one year high of $219.34. The firm has a market capitalization of $4.07 billion, a PE ratio of 47.22 and a beta of 0.79. The stock's 50-day moving average is $174.63 and its two-hundred day moving average is $171.10.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.35 by ($0.15). Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. Analysts expect that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the firm's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the sale, the chief accounting officer now directly owns 12,604 shares of the company's stock, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Krystal Biotech

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB acquired a new stake in shares of Krystal Biotech during the 3rd quarter valued at about $40,000. Franklin Resources Inc. raised its stake in shares of Krystal Biotech by 34.2% in the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company's stock valued at $43,774,000 after acquiring an additional 62,178 shares during the last quarter. Avanza Fonder AB bought a new stake in Krystal Biotech during the 4th quarter worth about $119,000. Crossmark Global Holdings Inc. increased its stake in shares of Krystal Biotech by 5.5% in the 4th quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company's stock valued at $362,000 after buying an additional 121 shares during the period. Finally, Janney Montgomery Scott LLC boosted its stake in shares of Krystal Biotech by 42.0% in the 4th quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company's stock valued at $8,239,000 after purchasing an additional 15,545 shares during the last quarter. 86.29% of the stock is owned by institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.